Scholarlink

<p>Acalabrutinib is a selective, covalent Bruton tyrosine kinase inhibitor approved in multiple countries for patients with chronic lymphocytic leukemia (CLL). Acalabrutinib is approved in China for patients with CLL who received ≥ 1 prior therapy. We report results from a randomized, multicenter, open-label, phase 3 study (NCT04075292) evaluating the efficacy and safety of acalabrutinib vs chlorambucil plus rituximab (C + R) in medically unfit patients with treatment-naive CLL in Asia. As of January 3, 2024, 155 patients (overall cohort: acalabrutinib, <i>n</i> = 77; C + R, <i>n</i> = 78; China cohort [mainland China and Taiwan], <i>n</i> = 53 and <i>n</i> = 50, respectively) were enrolled. With a median follow-up of 23.5 and 18.2 months in the overall and China cohorts, respectively, acalabrutinib demonstrated a 92% risk reduction of disease progression or death vs C + R (both cohorts: hazard ratio, 0.08; <i>P</i> &lt; 0.0001; primary endpoint). Overall response rates were 76.6% vs 71.8% with median duration of response not reached vs 11.6 months in the acalabrutinib vs C + R arms, respectively. In the acalabrutinib arm, no atrial fibrillation or hypertension events were observed. Efficacy and safety were consistent across cohorts. Acalabrutinib was well tolerated and demonstrated a progression-free survival benefit vs C + R in this Asian population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Acalabrutinib vs chlorambucil plus rituximab in untreated chronic lymphocytic leukemia: A randomized phase 3 Asian study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月19日

查看全文
  • Jia Li,
  • Shuhua Yi,
  • Thanh Nguyen,
  • Wenjuan Yu,
  • Keshu Zhou,
  • Haiwen Huang,
  • Udomsak Bunworasate,
  • Man Huynh,
  • Hui Zhou,
  • Su-Peng Yeh,
  • Yiqiu Wang,
  • Xiaofeng Liu,
  • Wei Fu,
  • Lugui Qiu

摘要

Acalabrutinib is a selective, covalent Bruton tyrosine kinase inhibitor approved in multiple countries for patients with chronic lymphocytic leukemia (CLL). Acalabrutinib is approved in China for patients with CLL who received ≥ 1 prior therapy. We report results from a randomized, multicenter, open-label, phase 3 study (NCT04075292) evaluating the efficacy and safety of acalabrutinib vs chlorambucil plus rituximab (C + R) in medically unfit patients with treatment-naive CLL in Asia. As of January 3, 2024, 155 patients (overall cohort: acalabrutinib, n = 77; C + R, n = 78; China cohort [mainland China and Taiwan], n = 53 and n = 50, respectively) were enrolled. With a median follow-up of 23.5 and 18.2 months in the overall and China cohorts, respectively, acalabrutinib demonstrated a 92% risk reduction of disease progression or death vs C + R (both cohorts: hazard ratio, 0.08; P < 0.0001; primary endpoint). Overall response rates were 76.6% vs 71.8% with median duration of response not reached vs 11.6 months in the acalabrutinib vs C + R arms, respectively. In the acalabrutinib arm, no atrial fibrillation or hypertension events were observed. Efficacy and safety were consistent across cohorts. Acalabrutinib was well tolerated and demonstrated a progression-free survival benefit vs C + R in this Asian population.